Leflunomide is an immunomodulatory disease modifying anti-rheumatic drug (DMARD) that is most commonly used in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis,[1–8] and studies are also currently investigating its therapeutic potential in kidney transplant recipients with BK-virus nephropathy.[9–11] The main aim of this review is to appraise the literature outlining the potential for dosage individualisation of leflunomide therapy in RA.
Personalized Medicine. 2014;11(4):449-461. © 2014 Future Medicine Ltd.